Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPrimorus Inv. Regulatory News (PRIM)

Share Price Information for Primorus Inv. (PRIM)

Share Price is delayed by 15 minutes
Get Live Data
3.70    0.00 (0.00%)
Bid:
3.40
Ask:
4.00
Spread: 0.60 (17.647%)
Market Cap: £4.61m
PRIM Live PriceLast checked at - London Stock Exchange

Intraday Primorus Inv. Share Chart

Investment Update

6 Apr 2021 07:00

RNS Number : 3924U
Primorus Investments PLC
06 April 2021
 

Primorus Investments plc

 

("Primorus" or the "Company")

Investment Update

Primorus (AIM: PRIM) is pleased to provide its shareholders with the following updates on a number of its investee companies.

Engage Technology Partners ("Engage"), the end-to-end workforce management platform provider, has recently completed an equity fundraising resulting in the conversion of loan notes which investors, including the Company, subscribed for last year as part of the Government's Future Fund initiative. Following the conversion, which was completed at a discount of 20 per cent. to the equity fundraising, Primorus now holds 92,374 ordinary shares in the capital of Engage, equating to approximately 4 per cent. of its fully diluted share capital.

Engage is an end-to-end workforce management platform that connects recruitment agencies, end hirers and contractors. Its cloud-based solution creates visibility across the paid to recruit process. As well as ensuring worker compliance, companies mitigate their tax liability risk. Cost management is made easier with transparency across companies' contractor pools. For more information, see: https://www.engagetech.com/

The Company is also pleased to provide an update on Zuuse Limited ("Zuuse"), a leading global software provider operating in the construction and building operations sector. Despite 2020 being a challenging year due to the global Covid-19 pandemic, Zuuse's revenue for the 12 months ending 31 December 2020 was up by 15 per cent. versus the comparable period last year and despite falling 7 per cent. during Q2 2020. The business was also EBITDA and cashflow positive throughout the period, which has provided a strong base moving into 2021 to increase the investment in the business to drive sales and revenue growth. Zuuse enjoyed record sales in December 2020. Management is optimistic that increased levels of investment in sales, marketing and product, along with an improving level of confidence in the economy, will result in a stronger trading performance in 2021; a view supported by results to date in 2021. For more information, see: www.zuuse.com

Primorus notes the announcement by TruSpine Technologies plc ("TruSpine") on 1 April that it has completed a share subscription to raise £585,000. Whilst the Company did not participate in the subscription, it is hoped the fundraise will further advance TruSpine through its FDA application process and commercial launch of its Cervi-LOK™ device. For more information, see http://truspine.org/ 

Rupert Labrum, Executive Chairman, commented: "We are pleased to continue our support of the Engage team. Whilst we did not invest in the recent fundraising, we have been impressed with the team and the business they have built. It has been promising to see the growth the business has enjoyed, particularly through the Covid-19 pandemic.

Likewise, the resilience of the Zuuse team, coupled with their leading software solutions, has been rewarded by the business's underlying performance. As confidence in the economy grows, we fully expect Zuuse to continue to execute its ambitious growth plans."

 

For further information, please contact:

Primorus Investments plc +44 (0) 20 8154 7907

Rupert Labrum

 

Nominated Adviser and Broker

Cairn Financial Advisers LLP +44 (0) 20 7213 0880

Sandy Jamieson / James Caithie

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGZGGDVMFGMZM
Date   Source Headline
2nd Jun 20269:35 amRNSFinal Results
24th Apr 20262:00 pmRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 20267:00 amRNSFurther Investment in Fresho Pty Ltd
10th Feb 20267:00 amRNSBoard role changes
15th Jan 20264:38 pmRNSHolding(s) in Company
9th Jan 20267:00 amRNSTransaction in Own Shares & TR1
8th Jan 20267:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSInvestee Company Update - Virtualstock
23rd Sep 20257:00 amRNSHalf-year Report
20th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20252:01 pmRNSHolding(s) in Company
6th Aug 20257:00 amRNSTransaction in Own Shares & TR-1
28th Jul 20257:00 amRNSTransaction in Own Shares
25th Jul 20257:00 amRNSHolding(s) in Company
24th Jul 20257:48 amRNSTransaction in Own Shares
18th Jul 20254:12 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSTransaction in Own Shares & TR-1
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 202512:30 pmRNSAnnouncement by Pri0r1ty Intelligence Group PLC
11th Jul 20258:03 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSHolding(s) in Company
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20251:35 pmRNSResult of AGM
25th Jun 202510:05 amRNSHoldings in Company
25th Jun 20257:00 amRNSInvestee Company Update - Pri0r1ty
13th Jun 20257:00 amRNSNotice of AGM & Proposed Rule 9 Waiver
30th May 20254:25 pmRNSFinal Results
31st Mar 20257:00 amRNSFurther Investment in Interpac Ltd
20th Jan 202511:00 amRNSDirector/PDMR Shareholding
20th Jan 202511:00 amRNSHolding(s) in Company
23rd Dec 20242:10 pmRNSInvestee Company Update – Alteration Earth
5th Nov 20247:00 amRNSSale Of Engage Shareholding
23rd Oct 202412:10 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSHolding(s) in Company
27th Sep 20245:05 pmRNSDirector/PDMR Shareholding
20th Sep 20241:10 pmRNSFurther Investment - Replacement
20th Sep 20247:00 amRNSFurther Investment in Fresho Pty Ltd
5th Sep 20247:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.